Fig. 5From: Mixed adenoneuroendocrine carcinoma with loss of HER2 positivity after trastuzumab-based chemotherapy for HER2-positive gastric cancer: a case reportRe-evaluation of the biopsy specimen before surgery of hematoxylin eosin (a), synaptophysin (b), chromogranin A (c), and CD56 (d)Back to article page